GATC Health's Derisq Named One of The Scientist’s 2026 Top Innovations
News related to:GATC Health · 2 min read
IRVINE, Calif., Sept. 29, 2026 /CourierPR/ -- GATC Health's Derisq has been named one of The Scientist’s 2026 Top Innovations, a recognition that highlights the company's groundbreaking AI report in the field of predictive risk intelligence. The Scientist, a trusted publication read by 330,000 subscribers and garnering 7.1 million pageviews annually, has been a cornerstone in the industry for 40 years. This accolade underscores the significance of Derisq in advancing life sciences research, biotechnology, and healthcare.
Derisq, powered by GATC Health’s proprietary Operon® AI platform, was selected as one of three winners in the Emerging Startup Technologies category. The platform uses in silico modeling to evaluate drug candidates and generate prospective insights into safety, efficacy, off-target effects, and potential clinical outcomes. This technology is designed to support biotech executives, pharmaceutical companies, investors, and other stakeholders in making high-stakes decisions about asset development, trial design, and capital allocation.
The underlying technology of Derisq has been independently evaluated by the University of California, Irvine, demonstrating 91% specificity in identifying off-target risks and 86% sensitivity in predicting target activation. This robust performance highlights the reliability and accuracy of the AI report in providing predictive intelligence before the commitment of development capital.
GATC Health, a tech-bio company revolutionizing drug discovery and development, aims to accelerate breakthroughs and reduce costly late-stage failures. By simulating complex human biology, Derisq accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. The company's technology is currently being used across biopharma, investment, and insurance applications to provide additional predictive intelligence before and during clinical development.
The Scientist’s Top Innovations competition, established in 2008, annually recognizes technologies and products that advance life sciences research and healthcare. Winners of the 2026 competition span four categories: biotechnology, lab research tools, healthcare and diagnostics, and emerging startup technologies. Derisq's inclusion in this prestigious list is a testament to the company's commitment to innovation and its potential to disrupt the market.
In summary, GATC Health's Derisq has been honored as one of The Scientist’s 2026 Top Innovations, recognizing its potential to transform drug discovery and development through advanced AI and predictive modeling. This recognition underscores the company's dedication to advancing the field and providing stakeholders with critical insights to inform their decisions.